NCT02170220View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Severe Hepatic Impairment
Interventions
DRUG

Vortioxetine

Vortioxetine tablets

Trial Locations (1)

Unknown

University of Miami, Miami

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY